London, ON, CANADA, Release: April 14, 2021 – Alimentiv Health Trust, the parent company of Alimentiv, Inc. (formerly Robarts Clinical Trials), a specialized global gastrointestinal (GI) contract research organization (CRO), and McDougall Scientific Ltd., a niche CRO, announced today the launch of AcelaBio, a commercial state-of-the-art research laboratory delivering histopathology and precision medicine services for… Continue reading Alimentiv Health Trust Launches AcelaBio (US) Inc. Today
Join our expert panel where they will discuss inflammatory bowel disease and NASH, two therapeutic areas that histopathology uses to determine eligibility and/or primary outcome measures. Our four experts will provide presentations on topics including Histopathology as a treatment target in IBD: Aspiration or Reality? Measuring histopathology in IBD trials Histopathology as a treatment target… Continue reading Implementation of Histopathology in GI Clinical Trials
Dr. Séverine Vermeire, Dr. Deanna Nguyen, and Dr. Niels Vande Casteele present Precision Medicine in IBD Clinical Research. Dr. Vermeire presenting how a translational medicine program successfully supported the development of a new compound – a gut-selective pan-Janus kinase inhibitor. Dr. Nguyen presenting The Application of Translational Medicine to Support an Early Drug Development Program… Continue reading Precision Medicine in IBD – From Clinical Research to Clinical Practice
10581 Roselle Street, Ste 110
San Diego, CA 92121
Tel: 1-877-357-9939
Fax: 1-858-264-1539
info@acelabio.com
